Targeted therapeutic options in early and metastatic NSCLC-overview
Pathol Oncol Res. 2024 Mar 28;30:1611715. doi: 10.3389/pore.2024.1611715. eCollection 2024.ABSTRACTThe complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therapy (osimertinib) in case of EGFR mutation. In oncogenic-addictive metastatic NSCLC, primarily in adenocarcinoma, the range of targeted therapies is expanding, with which the expected overall survival increases significantly, measure...
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Gabriella G álffy Éva Morócz R éka Korompay R éka Hécz R éka Bujdosó Rita Pusk ás T ímea Lovas Eszter G áspár Kamel Yahya P éter Király Zolt án Lohinai Source Type: research
Targeted therapeutic options in early and metastatic NSCLC-overview
Pathol Oncol Res. 2024 Mar 28;30:1611715. doi: 10.3389/pore.2024.1611715. eCollection 2024.ABSTRACTThe complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therapy (osimertinib) in case of EGFR mutation. In oncogenic-addictive metastatic NSCLC, primarily in adenocarcinoma, the range of targeted therapies is expanding, with which the expected overall survival increases significantly, measure...
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Gabriella G álffy Éva Morócz R éka Korompay R éka Hécz R éka Bujdosó Rita Pusk ás T ímea Lovas Eszter G áspár Kamel Yahya P éter Király Zolt án Lohinai Source Type: research
Targeted therapeutic options in early and metastatic NSCLC-overview
Pathol Oncol Res. 2024 Mar 28;30:1611715. doi: 10.3389/pore.2024.1611715. eCollection 2024.ABSTRACTThe complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therapy (osimertinib) in case of EGFR mutation. In oncogenic-addictive metastatic NSCLC, primarily in adenocarcinoma, the range of targeted therapies is expanding, with which the expected overall survival increases significantly, measure...
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Gabriella G álffy Éva Morócz R éka Korompay R éka Hécz R éka Bujdosó Rita Pusk ás T ímea Lovas Eszter G áspár Kamel Yahya P éter Király Zolt án Lohinai Source Type: research
Cancers, Vol. 16, Pages 1483: Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment & mdash;In Vitro, In Vivo and Clinical Trials Literature Review
This article delves into the latest advancements in therapeutic strategies targeting components of the tumor microenvironment and pivotal hallmarks of cancer: deregulating cellular metabolism and the Warburg effect, acidosis and hypoxia, the ability to metastasize and evade the immune system, aiming to enhance treatment efficacy while mitigating systemic toxicity. Insights from in vitro and in vivo studies and clinical trials underscore the promising effectiveness and elucidate the mechanisms of action of these novel therapeutic interventions for TNBC, particularly in cases refractory to conventional treatments. The integr...
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Anna Szulc Marta Wo źniak Tags: Review Source Type: research
Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors
ConclusionCombinatorial immunotherapeutic strategies involving PD-1/PD-L1 inhibitors hold considerable promise in the treatment of HER2-positive tumors. Continued research efforts and clinical trials are warranted to elucidate optimal treatment regimens that maximize therapeutic benefits while minimizing adverse effects. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - April 11, 2024 Category: Drugs & Pharmacology Source Type: research
Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial
CONCLUSIONS: In female patients with HER2-positive non-metastatic BC, neoadjuvant pyrotinib monotherapy plus taxanes appears to show promising clinical benefit and controllable AEs [Chinese Clinical Trial Registry (ChiCTR2100050870)]. The long-term efficacy and safety of this regime warrant further verification.PMID:38601287 | PMC:PMC11002487 | DOI:10.21037/gs-24-38 (Source: Hand Surgery)
Source: Hand Surgery - April 11, 2024 Category: Surgery Authors: Guolin Ye Peixian Chen Xiangwei Liu Tiancheng He Xavier Pivot Ruilin Pan Dan Zhou Lewei Zhu Kun Zhang Wei Li Shuqing Yang Jiawei Lin Gengxi Cai Huiqi Huang Source Type: research
Global representativeness and impact of funding sources in cost-effectiveness research on systemic therapies for advanced breast cancer: A systematic review
CONCLUSIONS: Breast cancer CE literature scarcely represents low-and-middle-income countries' perspectives and is influenced by pharmaceutical industry funding which targets European countries', frequently utilizes comparisons within same-drug class, and is more likely to have favorable conclusions.PMID:38603837 | DOI:10.1016/j.breast.2024.103727 (Source: Breast)
Source: Breast - April 11, 2024 Category: Cancer & Oncology Authors: Felippe Lazar Neto Marina Acevedo Zarzar de Melo Cassio Murilo Trovo Hidalgo Filho Maria Cec ília Mathias-Machado Laura Testa Alessandro Gon çalves Campolina Source Type: research
A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer
In this study we constructed a HER2/HER3-targeting bispecific ADC (BsADC) and characterized its physiochemical properties, target specificity and internalization in vitro, and assessed its anti-tumor activities in breast cancer cell lines and in animal models. The HER2/HER3-targeting BsADC had a drug to antibody ratio (DAR) of 2.89, displayed a high selectivity against the target JIMT-1 breast cancer cells in vitro, as well as a slightly higher level of internalization than HER2- or HER3-monospecific ADCs. More importantly, the bispecific ADC potently inhibited the viability of MCF7, JIMT-1, BT474, BxPC-3 and SKOV-3 cancer...
Source: Acta Pharmacologica Sinica - April 11, 2024 Category: Drugs & Pharmacology Authors: Hui-Fang Zong Xi Li Lei Han Lei Wang Jun-Jun Liu Ya-Li Yue Jie Chen Yong Ke Hua Jiang Yue-Qing Xie Bao-Hong Zhang Jian-Wei Zhu Source Type: research
Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial
CONCLUSIONS: In female patients with HER2-positive non-metastatic BC, neoadjuvant pyrotinib monotherapy plus taxanes appears to show promising clinical benefit and controllable AEs [Chinese Clinical Trial Registry (ChiCTR2100050870)]. The long-term efficacy and safety of this regime warrant further verification.PMID:38601287 | PMC:PMC11002487 | DOI:10.21037/gs-24-38 (Source: Hand Surgery)
Source: Hand Surgery - April 11, 2024 Category: Surgery Authors: Guolin Ye Peixian Chen Xiangwei Liu Tiancheng He Xavier Pivot Ruilin Pan Dan Zhou Lewei Zhu Kun Zhang Wei Li Shuqing Yang Jiawei Lin Gengxi Cai Huiqi Huang Source Type: research
Global representativeness and impact of funding sources in cost-effectiveness research on systemic therapies for advanced breast cancer: A systematic review
CONCLUSIONS: Breast cancer CE literature scarcely represents low-and-middle-income countries' perspectives and is influenced by pharmaceutical industry funding which targets European countries', frequently utilizes comparisons within same-drug class, and is more likely to have favorable conclusions.PMID:38603837 | DOI:10.1016/j.breast.2024.103727 (Source: Breast)
Source: Breast - April 11, 2024 Category: Cancer & Oncology Authors: Felippe Lazar Neto Marina Acevedo Zarzar de Melo Cassio Murilo Trovo Hidalgo Filho Maria Cec ília Mathias-Machado Laura Testa Alessandro Gon çalves Campolina Source Type: research
A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer
In this study we constructed a HER2/HER3-targeting bispecific ADC (BsADC) and characterized its physiochemical properties, target specificity and internalization in vitro, and assessed its anti-tumor activities in breast cancer cell lines and in animal models. The HER2/HER3-targeting BsADC had a drug to antibody ratio (DAR) of 2.89, displayed a high selectivity against the target JIMT-1 breast cancer cells in vitro, as well as a slightly higher level of internalization than HER2- or HER3-monospecific ADCs. More importantly, the bispecific ADC potently inhibited the viability of MCF7, JIMT-1, BT474, BxPC-3 and SKOV-3 cancer...
Source: Acta Pharmacologica Sinica - April 11, 2024 Category: Drugs & Pharmacology Authors: Hui-Fang Zong Xi Li Lei Han Lei Wang Jun-Jun Liu Ya-Li Yue Jie Chen Yong Ke Hua Jiang Yue-Qing Xie Bao-Hong Zhang Jian-Wei Zhu Source Type: research
Global representativeness and impact of funding sources in cost-effectiveness research on systemic therapies for advanced breast cancer: A systematic review
CONCLUSIONS: Breast cancer CE literature scarcely represents low-and-middle-income countries' perspectives and is influenced by pharmaceutical industry funding which targets European countries', frequently utilizes comparisons within same-drug class, and is more likely to have favorable conclusions.PMID:38603837 | DOI:10.1016/j.breast.2024.103727 (Source: Breast)
Source: Breast - April 11, 2024 Category: Cancer & Oncology Authors: Felippe Lazar Neto Marina Acevedo Zarzar de Melo Cassio Murilo Trovo Hidalgo Filho Maria Cec ília Mathias-Machado Laura Testa Alessandro Gon çalves Campolina Source Type: research
Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter]
(Source: Vascular Health and Risk Management)
Source: Vascular Health and Risk Management - April 11, 2024 Category: Cardiology Tags: Breast Cancer: Targets and Therapy Source Type: research
A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer
Acta Pharmacologica Sinica, Published online: 11 April 2024; doi:10.1038/s41401-024-01279-8A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - April 11, 2024 Category: Drugs & Pharmacology Authors: Hui-fang Zong Xi Li Lei Han Lei Wang Jun-jun Liu Ya-li Yue Jie Chen Yong Ke Hua Jiang Yue-qing Xie Bao-hong Zhang Jian-wei Zhu Source Type: research
Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis
CONCLUSIONS: Identified risk factors were consistent with the previous reports, and this study provides quantitative summary of risk factors for HR+/HER2- early breast cancer recurrence in Japan. (PROSPERO Registration ID, CRD42022338391.).PMID:38597173 | DOI:10.1080/03007995.2024.2332436 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Naoki Miyazaki Toshiki Iwasaki Hitomi Sakai Rurina Watanuki Yoshinori Tanizawa Zhihong Cai Tsutomu Kawaguchi Junji Tsurutani Kengo Nagashima Source Type: research
